Miller E
ICI Americas Inc., Wilmington, Delaware.
J Hum Hypertens. 1991 Dec;5 Suppl 2:49-51.
Two combinations of lisinopril and hydrochlorothiazide (L/HCTZ, 20 mg/12.5 mg and 20 mg/25 mg) are currently marketed. The licences are based primarily on a dose ratio study and a parallel titration study. In the former randomized study of 209 patients with sitting DBP of 90-115 mm Hg, the antihypertensive effects of L/HCTZ 20 mg/12.5 mg and 20 mg/25 mg were significantly greater than either lisinopril or hydrochlorothiazide monotherapy (P less than or equal to 0.01), while the effect of L/HCTZ 20 mg/6.25 mg, was greater than hydrochlorothiazide but not lisinopril monotherapy. In the latter study, 394 patients with sitting DBP of 90-120 mm Hg received lisinopril 20 mg, HCTZ 12.5 mg, or L/HCTZ 20 mg/12.5 mg once daily for 12 weeks of double-blind therapy. All of the dose regimens could be doubled at 4 and 8 weeks for adequate BP control. The L/HCTZ group had significantly greater effect than either monotherapy (P less than or equal to 0.01). Thus, concomitant therapy with lisinopril and hydrochlorothiazide provides BP reduction beyond that of either monocomponent. Studies on new combinations of lisinopril and hydrochlorothiazide are under way to increase prescribing options for practitioners.
赖诺普利和氢氯噻嗪的两种复方制剂（赖诺普利/氢氯噻嗪，20毫克/12.5毫克和20毫克/25毫克）目前已上市。这些许可主要基于一项剂量比研究和一项平行滴定研究。在前者针对209例坐位舒张压为90 - 115毫米汞柱的患者进行的随机研究中，20毫克/12.5毫克和20毫克/25毫克的赖诺普利/氢氯噻嗪的降压效果显著大于赖诺普利或氢氯噻嗪单药治疗（P≤0.01），而20毫克/6.25毫克的赖诺普利/氢氯噻嗪的效果大于氢氯噻嗪单药治疗，但不大于赖诺普利单药治疗。在后者的研究中，394例坐位舒张压为90 - 120毫米汞柱的患者在双盲治疗的12周内每天接受一次20毫克赖诺普利、12.5毫克氢氯噻嗪或20毫克/12.5毫克赖诺普利/氢氯噻嗪治疗。在第4周和第8周时，所有剂量方案均可加倍以充分控制血压。赖诺普利/氢氯噻嗪组的效果显著大于单药治疗组（P≤0.01）。因此，赖诺普利和氢氯噻嗪联合治疗降低血压的效果超过了任何一种单一组分。关于赖诺普利和氢氯噻嗪新复方制剂的研究正在进行中，以增加从业者的处方选择。
